GNLX
$2.62
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Recent News
Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value
Key Insights The considerable ownership by retail investors in Genelux indicates that they collectively have a greater...
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
3 Promising Penny Stocks With Market Caps Under $200M
Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compelling area of interest for investors looking for potential growth opportunities. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials. Let's explore several such penny stocks that stand out for their...
June 2025's Promising Penny Stocks For Savvy Investors
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance...
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
Genelux Corporation (GNLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).